Other indications for Xanamem

 

DIABETES – COGNITIVE IMPAIRMENT

For many years, raised cortisol has been recognised as a feature of diabetes, and Type 2 diabetes in particular. Unfortunately, drugs developed to reduce cortisol levels as a treatment for diabetes have not been successful, showing little clinical benefit. A small pilot study demonstrated a potential cognitive benefit in diabetics through inhibiting excess cortisol production. Individuals with Type 2 diabetes have twice the risk of developing dementia than the general population. Our collaborators at the University of Edinburgh are interested in exploring these observations further. Discussions between Actinogen Medical and the University of Edinburgh for a Phase II trial of Xanamem in Diabetes Cognitive Impairment, partially supported by Actinogen, are ongoing.

Type 2 Diabetes is a chronic disease that affects over 422 million people globally. Current treatments control blood glucose levels but have no effect on preventing dementia. If effective, Xanamem could have an enormous impact on the global burden of this disease.